| HIV-1 induced bystander apoptosis H Garg, J Mohl, A Joshi Viruses 4 (11), 3020-3043, 2012 | 169 | 2012 |
| Strategies for targeted nonviral delivery of siRNAs in vivo SS Kim, H Garg, A Joshi, N Manjunath Trends in molecular medicine 15 (11), 491-500, 2009 | 150 | 2009 |
| Preferential replication of FIV in activated CD4+ CD25+ T cells independent of cellular proliferation A Joshi, TW Vahlenkamp, H Garg, WAF Tompkins, MB Tompkins Virology 321 (2), 307-322, 2004 | 94 | 2004 |
| Development of virus-like-particle vaccine and reporter assay for Zika virus H Garg, M Sedano, G Plata, EB Punke, A Joshi Journal of virology 91 (20), 10.1128/jvi. 00834-17, 2017 | 93 | 2017 |
| Virus like particles (VLP) as multivalent vaccine candidate against chikungunya, Japanese encephalitis, yellow fever and zika virus H Garg, T Mehmetoglu-Gurbuz, A Joshi Scientific Reports 10 (1), 4017, 2020 | 84 | 2020 |
| GGA and Arf proteins modulate retrovirus assembly and release A Joshi, H Garg, K Nagashima, JS Bonifacino, EO Freed Molecular cell 30 (2), 227-238, 2008 | 80 | 2008 |
| Role of HIV Gp41 mediated fusion/hemifusion in bystander apoptosis H Garg, R Blumenthal Cellular and molecular life sciences 65, 3134-3144, 2008 | 74 | 2008 |
| Studies on the immunostimulant and antihepatotoxic activities of Asparagus racemosus root extract. S Muruganandan, HG Himanshu Garg, JL Jawahar Lal, ... | 67 | 2001 |
| HIV gp41-induced apoptosis is mediated by caspase-3-dependent mitochondrial depolarization, which is inhibited by HIV protease inhibitor nelfinavir H Garg, R Blumenthal Journal of leukocyte biology 79 (2), 351-362, 2006 | 62 | 2006 |
| Preferential Feline Immunodeficiency Virus (FIV) Infection of CD4+ CD25+ T-Regulatory Cells Correlates both with Surface Expression of CXCR4 and Activation of … A Joshi, H Garg, MB Tompkins, WA Tompkins Journal of virology 79 (8), 4965-4976, 2005 | 62 | 2005 |
| Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv K Loomis, B Smith, Y Feng, H Garg, A Yavlovich, R Campbell-Massa, ... Experimental and molecular pathology 88 (2), 238-249, 2010 | 55 | 2010 |
| Site-specific mutations in HIV-1 gp41 reveal a correlation between HIV-1-mediated bystander apoptosis and fusion/hemifusion H Garg, A Joshi, EO Freed, R Blumenthal Journal of Biological Chemistry 282 (23), 16899-16906, 2007 | 54 | 2007 |
| Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion SA Gallo, JD Reeves, H Garg, B Foley, RW Doms, R Blumenthal Retrovirology 3, 1-8, 2006 | 49 | 2006 |
| Glycoside analogs of β-galactosylceramide, a novel class of small molecule antiviral agents that inhibit HIV-1 entry H Garg, N Francella, KA Tony, LA Augustine, JJ Barchi Jr, J Fantini, A Puri, ... Antiviral research 80 (1), 54-61, 2008 | 48 | 2008 |
| Host and viral factors in HIV-mediated bystander apoptosis H Garg, A Joshi Viruses 9 (8), 237, 2017 | 44 | 2017 |
| Cardiovascular complications of HIV infection and treatment H Garg, A Joshi, D Mukherjee Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly …, 2013 | 42 | 2013 |
| HIV ENV glycoprotein-mediated bystander apoptosis depends on expression of the CCR5 co-receptor at the cell surface and ENV fusogenic activity A Joshi, AM Nyakeriga, R Ravi, H Garg Journal of Biological Chemistry 286 (42), 36404-36413, 2011 | 42 | 2011 |
| Mechanism of feline immunodeficiency virus envelope glycoprotein-mediated fusion H Garg, FJ Fuller, WAF Tompkins Virology 321 (2), 274-286, 2004 | 41 | 2004 |
| Improved nonviral cancer suicide gene therapy using survivin promoter-driven mutant Bax H Garg, R Salcedo, G Trinchieri, R Blumenthal Cancer gene therapy 17 (3), 155-163, 2010 | 40 | 2010 |
| Targeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapy H Garg, M Viard, A Jacobs, R Blumenthal Current topics in medicinal chemistry 11 (24), 2947-2958, 2011 | 38 | 2011 |
